9,10-seco-cyclopentanohydrophenanthrene Ring System Or 9,10-seco Cyclopentanohydrophenanthrene Ring System Having A Bond Between The 3- And 5-positions (e.g., Vitamin D Compounds, Cholecalciferols, Activated 7-dehydrocholesterols, Dihydrotachysterols, 3,5 Cyclovitamin D Compounds, Etc.) Patents (Class 552/653)
-
Patent number: 7232810Abstract: 2-Methylene-19-nor-24(S) and 24(R) derivatives of 1?,25-dihydroxyvitamin D2 are disclosed. These compounds are characterized by minimal bone calcium mobilization activity and relatively high intestinal calcium transport activity. This results in novel therapeutic agents for the treatment of diseases such as renal osteodystrophy, autoimmune diseases, and osteoporosis.Type: GrantFiled: August 18, 2004Date of Patent: June 19, 2007Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Rafal R. Sicinski, Sumithra Gowlugari
-
Patent number: 7214670Abstract: This invention provides pharmaceutical uses for 2-methylene-19-nor-20(S)-1?,25-dihydroxyvitamin D3. Administration of this compound increases the life expectancy of human beings, especially elderly human beings. In particular, it increases the survival rate of females lacking estrogen, especially post-menopausal females, and reduces mortality resulting from spontaneous development of malignant tumors in both males and females.Type: GrantFiled: September 24, 2003Date of Patent: May 8, 2007Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Lori A. Plum, Margaret Clagette-Dame
-
Patent number: 7214671Abstract: This invention provides pharmaceutical uses for 2-methylene-19-nor-20(S)-1?,25-dihydroxyvitamin D3. This compound is characterized by high bone calcium mobilization activity demonstrating preferential activity on bone. This results in a novel therapeutic agent for the treatment and prophylaxis of diseases where bone formation is desired, particularly osteoporosis. This compound also increases both breaking strength and crushing strength of bones evidencing use in conjunction with bone replacement surgery such as hip and knee replacements, as well as use by normal subjects when high bone mass is desired.Type: GrantFiled: February 19, 2004Date of Patent: May 8, 2007Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Lori A. Plum, Margaret Clagette-Dame
-
Patent number: 7211680Abstract: Compounds of Formula I, wherein Y1, Y2, R1–R6, Q and Z are as defined herein, are vitamin D derivatives. These compounds are useful for, e.g., the treatment hyperprolifierative diseases of the skin, tumor diseases and precancerous stages, auto-immune diseases, rejection reactions in the case of autologous, allogenic or xenogenic transplants, AIDS, atopic skin conditions, secondary hyperparathyroidism, renal osteodystrophia, senile and postmenopausal osteoporosis, diabetes mellitus type II, degenerative diseases of the peripheral and central nervous system, hypercalcemias, granulomatous diseases, paraneoplastic hypercalcemias, hypercalcemias in hyperparathyroidism, hirsutism, ateriosclerosis, and/or inflammatory diseases.Type: GrantFiled: September 10, 2003Date of Patent: May 1, 2007Assignee: Schering AktiengesellschaftInventors: Andreas Steinmeyer, Gerald Kirsch, Guenter Neef, Katiea Schwarz, Ruth Thieroff-Ekerdt, Herbert Wiesinger, Martin Haberey, Marianne Fahnrich
-
Patent number: 7208484Abstract: A method of making 1?-hydroxy-2-methylene-19-nor-homopregnacalciferol. The method includes the steps of condensing a bicyclic ketone with an allylic phosphine oxide to produce a protected 19-nor-pregnacalciferol analog, thereafter cleaving the protecting group to form 22-alcohol, converting the alcohol to an ester, reducing the ester to 17?-isopropyl-19-nor-vitamin D analog, and finally deprotecting the 17?-isopropyl derivative to form the desired compound.Type: GrantFiled: May 17, 2004Date of Patent: April 24, 2007Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Sumithra Gowlugari, Rafal R. Sicinski
-
Patent number: 7205420Abstract: Provided is a method of general applicability of epimerizing a vitamin-D analog having an asymmetric allylic carbon atom at the C-24 position. The method is of particular utility in making calcipotriene.Type: GrantFiled: June 11, 2003Date of Patent: April 17, 2007Assignee: Teva Pharmaceutical Industries Ltd.Inventors: Evgeny Shapiro, Reinhard Effenberger, Asher Maymon, Anchel Schwartz
-
Patent number: 7205286Abstract: This invention discloses (20S)-1?-hydroxy-2?-methyl-19-nor-vitamin D3 and (20S)-1?-hydroxy-2?-methyl-19-nor-vitamin D3 and pharmaceutical uses therefor. These compounds exhibit pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. These compounds also have very significant calcemic activity and therefore may be used to treat immune disorders in humans as well as metabolic bone diseases such as osteoporosis.Type: GrantFiled: January 22, 2004Date of Patent: April 17, 2007Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Rafal R. Sicinski, Pawel K. Grzywacz
-
Patent number: 7166585Abstract: The present invention provides novel C24-sulfone analogs of 1?,25-dihydroxy vitamin D3, compositions comprising these compounds and methods of using these compounds as selective inhibitors of CYP24. In particular, the compounds of the invention are useful for treating diseases which benefit from a modulation of the levels of 1?,25-dihydroxy vitamin D3, for example, cell-proliferative disorders.Type: GrantFiled: July 3, 2003Date of Patent: January 23, 2007Assignees: Cytochroma Inc., Johns Hopkins UniversityInventors: Gary H. Posner, Kenneth Crawford, Hong Woon Yang, HeungBae Jeon, Mark Hatcher, Byung-Chul Suh, Jay White, Glenville Jones
-
Patent number: 7115758Abstract: The invention relates to vitamin D derivatives of general formula I, process for their production, intermediate products of the process as well as the use for the production of pharmaceutical agents.Type: GrantFiled: November 26, 2002Date of Patent: October 3, 2006Assignee: Schering AGInventors: Andreas Steinmeyer, Katica Schwarz, Claudia Giesen, Martin Haberey, Marianne Fähnrich
-
Patent number: 7112579Abstract: This invention provides a novel class of vitamin D related compounds, namely, the 2-alkyl-19-nor-vitamin D derivatives, as well as a general method for their chemical synthesis. The compounds have the formula: where Y1 and Y2, which may be the same or different, are each selected from the group consisting of hydrogen and a hydroxy-protecting group, R6 is selected from the group consisting of alkyl, hydroxyalkyl and fluoroalkyl, and where the group R represents any of the typical side chains known for vitamin D type compounds. These 2-substituted compounds, especially the 2?-methyl and the 2?-methyl-20S derivatives, are characterized by relatively high intestinal calcium transport activity and relatively high bone calcium mobilization activity resulting in novel therapeutic agents for the treatment of diseases where bone formation is desired, particularly low bone turnover osteoporosis.Type: GrantFiled: October 10, 2003Date of Patent: September 26, 2006Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Rafal R. Sicinski
-
Patent number: 7101865Abstract: The present invention provides novel sulfoximine compounds, compositions comprising these compounds and methods of using these compounds as inhibitors of CYP24. In particular, the compounds of the invention are useful for treating diseases which benefit from a modulation of the levels of 1?,25-dihydroxy vitamin D3, for example, cell-proliferative disorders.Type: GrantFiled: June 13, 2003Date of Patent: September 5, 2006Assignees: Cytochroma Inc., Johns Hopkins Univ.Inventors: Gary H. Posner, Mehmet Kahraman, Uttam Saha
-
Patent number: 7094916Abstract: This invention discloses (20S)-1?-hydroxy-2?-methyl-19-nor-vitamin D3 and (20S)-1?-hydroxy-2?-methyl-19-nor-vitamin D3 and pharmaceutical uses therefor. These compounds exhibit pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. These compounds also have very significant calcemic activity and therefore may be used to treat immune disorders in humans as well as metabolic bone diseases such as osteoporosis.Type: GrantFiled: January 18, 2005Date of Patent: August 22, 2006Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Rafal R. Sicinski, Pawel K. Grzywacz
-
Patent number: 7094776Abstract: A method of modifying or altering the structure of a 1?-hydroxylated vitamin D compound to increase its biological activity by altering the conformational equilibrium of the A-ring to favor a chair conformation that presents the 1?-hydroxyl in the axial orientation. This is accomplished by either locking the A-ring chair conformation in a geometry having an axially orientated 1?-hydroxyl, or by the addition of one or more substituents to the A-ring which interact with other substituents in the molecule or on the A-ring to provide a driving force to the A-ring to adopt a chair conformation which presents the 1?-hydroxyl in the axial orientation.Type: GrantFiled: March 18, 2005Date of Patent: August 22, 2006Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Rafal R. Sicinski
-
Patent number: 7094775Abstract: The invention provides therapeutic methods for inhibiting, ameliorating or alleviating the hyperproliferative cellular activity of diseases of the breast, e.g., breast cancer, which includes administering to a patient in need thereof an active vitamin D analogue and another anticancer agent. Cell differentiation is promoted, induced or enhanced without causing to the patient dose-limiting hypercalcemia and hypercalciuria.Type: GrantFiled: June 30, 2004Date of Patent: August 22, 2006Assignee: Bone Care International, LLCInventors: Stephen A. Strugnell, Don Wigington
-
Patent number: 7094774Abstract: This invention provides a novel class of vitamin D related compounds, namely, the 2-alkylidene-19-nor-vitamin D derivatives, as well as a general method for their chemical synthesis. The compounds have the formula: where Y1 and Y2, which may be the same or different, are each selected from the group consisting of hydrogen and a hydroxy-protecting group, R6 and R8, which may be the same or different, are each selected from hydrogen, alkyl, hydroxyalkyl and fluoroalkyl, or when taken together represent the group —(CH2)x— where x is an integer from 2 to 5, and where the group R represents any of the typical side chains known for vitamin D type compounds. These 2-substituted compounds are characterized by relatively high intestinal calcium transport activity and relatively high bone calcium mobilization activity resulting in novel therapeutic agents for the treatment of diseases where bone formation is desired, particularly low bone turnover osteoporosis.Type: GrantFiled: February 17, 2004Date of Patent: August 22, 2006Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Rafal R. Sicinski
-
Patent number: 7074777Abstract: The object of the present invention is to provide a vitamin D derivative exhibiting excellent physiological activity as medicines, in particular as therapeutic agents for skin disease including psoriasis, and having decreased hypercalcemic activity. The present invention provides vitamin D derivatives represented by the general Formula (1): wherein in Formula (1), X is oxygen or sulfur; R1 is hydrogen or Formula (2) R2 is hydrogen or alkyl; R3 and R4 are hydrogen or alkyl or R3 and R4 together form a double bond between the 16- and 17-positions; R5 is hydrogen or —OR13 in which R13 is hydrogen or a protecting group; and R6 is hydrogen or a protecting group.Type: GrantFiled: April 18, 2001Date of Patent: July 11, 2006Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Akira Kawase, Hitoshi Shimizu, Kazuki Shimizu, Takashi Emura, Kazutomo Kinoshita
-
Patent number: 7071179Abstract: A method of modifying or altering the structure of a 1?-hydroxylated vitamin D compound to increase its biological activity by altering the conformational equilibrium of the A-ring to favor a chair conformation that presents the 1?-hydroxyl in the axial orientation. This is accomplished by either locking the A-ring chair conformation in a geometry having an axially orientated 1?-hydroxyl, or by the addition of one or more substituents to the A-ring which interact with other substituents in the molecule or on the A-ring to provide a driving force to the A-ring to adopt a chair conformation which presents the 1?-hydroxyl in the axial orientation.Type: GrantFiled: March 18, 2005Date of Patent: July 4, 2006Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Rafal R. Sicinski
-
Patent number: 7071344Abstract: The invention relates to novel vitamin D derivatives of general formula (I), a method for the production thereof, intermediate products of the method and the utilization of vitamin D derivatives for producing medicaments.Type: GrantFiled: September 29, 1998Date of Patent: July 4, 2006Assignee: Schering AGInventors: Andreas Steinmeyer, Gunter Neef, Gerald Kirsch, Katica Schwarz, Herbert Wiesinger, Martin Haberey, Marianne Fahnrich, Gernot Langer
-
Patent number: 7064115Abstract: This invention discloses (20S)-1?-hydroxy-2?-methyl-19-nor-vitamin D3 and (20S)-1?-hydroxy-2?-methyl-19-nor-vitamin D3 and pharmaceutical uses therefor. These compounds exhibit pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. These compounds also have very significant calcemic activity and therefore may be used to treat immune disorders in humans as well as metabolic bone diseases such as osteoporosis.Type: GrantFiled: January 22, 2004Date of Patent: June 20, 2006Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Rafal R. Sicinski, Pawel K. Grzywacz
-
Patent number: 7056904Abstract: A method of modifying or altering the structure of a 1?-hydroxylated vitamin D compound to increase its biological activity by altering the conformational equilibrium of the A-ring to favor a chair conformation that presents the 1?-hydroxyl in the axial orientation. This is accomplished by either locking the A-ring chair conformation in a geometry having an axially orientated 1?-hydroxyl, or by the addition of one or more substituents to the A-ring which interact with other substituents in the molecule or on the A-ring to provide a driving force to the A-ring to adopt a chair conformation which presents the 1?-hydroxyl in the axial orientation.Type: GrantFiled: March 18, 2005Date of Patent: June 6, 2006Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Rafal R. Sicinski
-
Patent number: 7053075Abstract: A treatment for obesity and overweight comprises administering a vitamin D analog. The analog effectively inhibits an increase in body fat to animals at risk and decreases the basal fat content of animals. The treatment has a positive effect on the lean body component such that while there is an overall decrease in body weight, there is also a decrease in percent body fat. This decrease can be proportionally greater than the overall decrease in body weight. In addition, the treatment has a positive effect on bone turnover and osteogenesis making the vitamin D analog a beneficial treatment for the symptoms of menopause. Various exemplary embodiments of the treatment use the 2-alkylidene derivatives of vitamin D3, such as the 2-alkylidene-19-nor derivatives in both the R and S configurations at carbon-20.Type: GrantFiled: November 24, 2004Date of Patent: May 30, 2006Inventors: Hector F. DeLuca, Lori A. Plum, Hau Zhe Ke, Thomas A. Brown
-
Patent number: 6989377Abstract: The present invention relates to therapeutics for the prevention and treatment of vitamin D responsive diseases in humans, as well as other animals, through the use of biologically active vitamin D compounds in combination with at least one other immunomodulatory compound such as interleukin-10, interleukin-4, or a TNF? inhibitor.Type: GrantFiled: June 13, 2002Date of Patent: January 24, 2006Assignee: Wisconsin Alumni Research FoundationInventors: Colleen E. Hayes, Faye E. Nashold
-
Patent number: 6982257Abstract: Provided are 1,25-dihydroxy-2-methylvitamin D3 derivatives expressed by the general formula (I), [wherein each of R1 and R2 is independently a hydrogen atom or a tri(C1 to C7 alkyl)silyl group; herein configurations of asymmetric carbons at the 1-, 2- and 3-positions are each independently ?-configuration or ?-configuration] and their production methods. The compound is useful as a treating agent for osteoporosis, rickets, hyperthyroidism, etc.Type: GrantFiled: April 30, 1998Date of Patent: January 3, 2006Assignee: Teijin LimitedInventors: Hiroaki Takayama, Katsuhiro Konno, Toshie Fujishima
-
Patent number: 6982258Abstract: The present invention provides novel 16-ene-C25-oxime and 16-ene-C-25-oxime ether analogs of 1?,25-dihydroxy vitamin D3, compositions comprising these compounds and methods of using these compounds as inhibitors of CYP24. In particular, the compound of Formula I are useful for treating diseases which benefit from a modulation of the levels of 1?,25-dihydroxy vitamin D3, for example, cell-proliferative disorders.Type: GrantFiled: October 15, 2002Date of Patent: January 3, 2006Assignees: Cytochroma Inc., Johns Hopkins UniversityInventors: Gary Posner, Mehmet Kahraman, Heung Bae Jeon, Jay A. White, Glenville Jones, Bethany Halford
-
Patent number: 6903083Abstract: The invention provides a stabilized 1?-hydroxyvitamin D (“SHVD”) which is particularly well suited for pharmaceutical formulations.Type: GrantFiled: August 20, 2002Date of Patent: June 7, 2005Assignee: Bone Care International, Inc.Inventors: Joyce C. Knutson, Richard B. Mazess, Charles W. Bishop
-
Patent number: 6900191Abstract: A compound of formula I: wherein R1 is hydrogen, R2 is —CH3, R3 is —CH3, and R4 is hydrogen, useful in cancer prevention and therapy.Type: GrantFiled: January 20, 1998Date of Patent: May 31, 2005Assignee: OncQuest, Inc.Inventors: Robert M. Moriarty, Raju A. Penmasta, Liang Guo, Munagala S. Rao, Rajendra G. Mehta
-
Patent number: 6894037Abstract: This invention provides a novel vitamin D analog, namely, 2-methylene-19-nor-20(S)-25-methyl-1?-hydroxycalciferol. The compound has the formula: This 2-substituted compound is characterized by relatively high intestinal calcium transport activity and relatively low bone calcium mobilization activity resulting in novel therapeutic agents for the treatment of diseases where bone formation is desired, particularly osteoporosis. These compounds also exhibit pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as anti-cancer agents and for the treatment of diseases such as psoriasis.Type: GrantFiled: September 8, 2003Date of Patent: May 17, 2005Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Pawel K. Grzywacz
-
Patent number: 6890914Abstract: A method of modifying or altering the structure of a 1?-hydroxylated vitamin D compound to increase its biological activity by altering the conformational equilibrium of the A-ring to favor a chair conformation that presents the 1?-hydroxyl in the axial orientation. This is accomplished by either locking the A-ring chair conformation in a geometry having an axially orientated 1?-hydroxyl, or by the addition of one or more substituents to the A-ring which interact with other substituents in the molecule or on the A-ring to provide a driving force to the A-ring to adopt a chair conformation which presents the 1?-hydroxyl in the axial orientation.Type: GrantFiled: September 11, 2002Date of Patent: May 10, 2005Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Rafal R. Sicinski
-
Patent number: 6867313Abstract: Compounds expressed by the following general formula (1), [wherein, R01 and R02 are each independently a hydrogen atom or a protecting group for a hydroxyl group; Z is one out of the following formulae (1-1) to (1-5)]. The compounds can be used as active ingredients of treating agents for inflammatory respiratory diseases, malignant tumors, rheumatoid arthritis, osteoporosis, diabetes mellitus, hypertension, alopecia, acne, psoriasis, dermatitis, hypercalcemia, hypoparathyroidism and metabolic disorder of cartilage.Type: GrantFiled: January 4, 2002Date of Patent: March 15, 2005Assignee: Teijin LimitedInventors: Kazuya Takenouchi, Qingzhi Gao, Kenji Manabe, Ryo Sogawa, Yasuhiro Takano, Seiichi Ishizuka
-
Patent number: 6858595Abstract: Methods of treating inflammatory bowel disease are described, and in particular the prevention and treatment of inflammatory bowel disease in humans as well as other animals. These methods involve the administration of biologically active vitamin D compounds, and therapeutic compositions thereof, so that the symptoms of Inflammatory Bowel Disease are reduced or relieved.Type: GrantFiled: December 21, 2001Date of Patent: February 22, 2005Assignee: Wisconsin Alumni Research AssociationInventors: Colleen E. Hayes, Faye E. Nashold
-
Patent number: 6846811Abstract: This invention discloses (20S)-1?-hydroxy-2?-methyl-19-nor-vitamin D3 and (20S)-1?-hydroxy-25-methyl-19-nor-vitamin D3 and pharmaceutical uses therefor. These compounds exhibit pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anticancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. These compounds also have very significant calcemic activity and therefore may be used to treat immune disorders in humans as well as metabolic bone diseases such as osteoporosis.Type: GrantFiled: April 22, 2002Date of Patent: January 25, 2005Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Rafal R. Sicinski, Pawel K. Grzywacz
-
Patent number: 6844457Abstract: This invention discloses (20S)-1?-hydroxy-2?-methyl-19-nor-vitamin D3 and (20S)-1?-hydroxy-2?-methyl-19-nor-vitamin D3 and pharmaceutical uses therefor. These compounds exhibit pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. These compounds also have very significant calcemic activity and therefore may be used to treat immune disorders in humans as well as metabolic bone diseases such as osteoporosis.Type: GrantFiled: January 22, 2004Date of Patent: January 18, 2005Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Rafal R. Sicinski, Pawel K. Grzywacz
-
Patent number: 6844330Abstract: This invention discloses (20S)-1?-hydroxy-2?-methyl-19-nor-vitamin D3 and (20S)-1?-hydroxy-2?-methyl-19-nor-vitamin D3 and pharmaceutical uses therefor. These compounds exhibit pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. These compounds also have very significant calcemic activity and therefore may be used to treat immune disorders in humans as well as metabolic bone diseases such as osteoporosis.Type: GrantFiled: January 22, 2004Date of Patent: January 18, 2005Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Rafal R. Sicinski, Pawel K. Grzywacz
-
Patent number: 6844331Abstract: This invention discloses (20S)-1?-hydroxy-2?-methyl-19-nor-vitamin D3 and (20S)-1?-hydroxy-2?-methyl-19-nor-vitamin D3 and pharmaceutical uses therefor. These compounds exhibit pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. These compounds also have very significant calcemic activity and therefore may be used to treat immune disorders in humans as well as metabolic bone diseases such as osteoporosis.Type: GrantFiled: January 22, 2004Date of Patent: January 18, 2005Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Rafal R. Sicinski, Pawel K. Grzywacz
-
Patent number: 6844332Abstract: This invention discloses (20S)-1?-hydroxy-2?-methyl-19-nor-vitamin D3 and (20S)-1?-hydroxy-2?-methyl-19-nor-vitamin D3 and pharmaceutical uses therefor. These compounds exhibit pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. These compounds also have very significant calcemic activity and therefore may be used to treat immune disorders in humans as well as metabolic bone diseases such as osteoporosis.Type: GrantFiled: January 22, 2004Date of Patent: January 18, 2005Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Rafal R. Sicinski, Pawel K. Grzywacz
-
Patent number: 6835723Abstract: A method of purifying 2-methylene-19-nor-20(S)-1&agr;-hydroxy-bis-homo-pregnacaciferol to obtain 2-methylene-19-nor-20(S)-1&agr;-hydroxy-bis-homo-pregnacalciferol in crystalline form. The method includes the steps of boiling a solvent such as acetone under inert atmosphere, dissolving a product containing 2-methylene-19-nor-20(S)-1&agr;-hydroxy-bis-homo-pregnacalciferol to be purified in the solvent, cooling the solvent and dissolved product below ambient temperature for a sufficient amount of time to form a precipitate of 2-methylene-19-nor-20(S)-1&agr;-hydroxy-bis-homo-pregnacalciferol crystals, and recovering the 2-methylene-19-nor-20(S)-1&agr;-hydroxy-bis-homo-pregnacalciferol crystals.Type: GrantFiled: December 12, 2002Date of Patent: December 28, 2004Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, James B. Thoden, Hazel M. Holden, Margaret Clagett-Dame, Sumithra Gowlugari, Pawel Grzywacz
-
Patent number: 6831183Abstract: The present invention provides crystals of the compound represented by formula (I): ;crystals of a vitamin D derivative which are obtained by purifying a crude or preliminarily purified product of the vitamin D derivative through a reverse phase chromatography and then crystallizing the purified derivative from an organic solvent; novel compounds which are formed during the synthesis of a vitamin D derivative as by-product; and a method for purifying a vitamin D derivative or the precursor thereof. The method of the present invention makes it possible to supply a highly purified vitamin D derivative, especially ED-71, in bulk and steadily.Type: GrantFiled: July 12, 2002Date of Patent: December 14, 2004Assignee: Chugai Seiy aku Kabushiki KaishaInventor: Tsuyoshi Yamauchi
-
Publication number: 20040229851Abstract: 2-propylidene-19-nor-vitamin D compounds are disclosed as well as pharmaceutical uses for these compounds and methods of synthesizing these compounds. These compounds are characterized by high bone calcium mobilization activity and high intestinal calcium transport activity. This results in novel therapeutic agents for the treatment and prophylaxis of diseases where bone formation is desired, particularly osteoporosis, as well as autoimmune diseases such as multiple sclerosis, diabetes mellitus and lupus. These compounds also exhibit pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis. These compounds also increase both breaking strength and crushing strength of bones evidencing use in conjunction with bone replacement surgery such as hip and knee replacements.Type: ApplicationFiled: April 9, 2004Publication date: November 18, 2004Inventors: Hector F. DeLuca, Rafal R. Sicinski, Agnieszka Glebocka, Lori A. Plum
-
Publication number: 20040224929Abstract: Novel vitamin D analogs, markedly active in the fields of cell proliferation and differentiation, are selected from among (4E,6E)-7-{3-[2-(3,4-bis-hydroxymethylphenyl)-ethyl] phenyl}-3-ethylnona-4, 6-dien-3-ol, (E)-6-[3-(3,4-bis-hydroxymethylbenzyloxy)phenyl]1,1,1-trifluoro-2-trifluoromethyloct-5-en-3-yn-2-ol, (3E,5E)-6-[3-(3 ,4-bis-hydro xymethylbenzyloxy)-phenyl]-1,1,1-trifluoro-2-trifluoromethylocta-3,5-dien-2-ol, (E)-6-{3-[2-(3,4-bis-hydroxymethylphenyl)ethyl]phenyl }-1,1,1-trifluoro-2-trifluoromethyloct-5-en-3-yn-2-ol, and (3E,5E)-6-{3-[2-(3,4-bis-hydroxymethylphenyl)-ethyl] phenyl-1,1,1-trifluoro-2-trifluoromethylocta-3,5-dien-2-ol, and the geometric isomers thereof and these compounds in which one or more of the hydroxyl functions are protected by a protective group —(C═O)—R, in which R is a linear or branched alkyl radical having from 1 to 6 carbon atoms, an aryl radical having from 6 to 10 carbon atoms, or anType: ApplicationFiled: November 24, 2003Publication date: November 11, 2004Applicant: GALDERMA RESEARCH & DEVELOPMENT, S.N.C.Inventor: Jean-Michel Bernardon
-
Publication number: 20040224930Abstract: The present invention provides novel D-ring and side-chain analogs of 1&agr;,25-dihydroxyvitamin D3, compositions comprising these compounds and methods of using these compounds as selective inhibitors of CYP24. In particular, the compounds of the invention are useful for treating diseases which benefit from a modulation of the levels of 1&agr;,25-dihydroxyvitamin D3, for example, cell-proliferative disorders.Type: ApplicationFiled: December 18, 2003Publication date: November 11, 2004Inventors: Gary H. Posner, Jae Kyoo Lee, Qiang Wang, Kenneth R. Crawford, Hong Woon Yang, Steven M. Silverman, Byung-Chul Suh, Jay A. White, Glenville Jones, Uttam Saha, Heung Bae Jeon
-
Publication number: 20040220418Abstract: A method of making 1&agr;-hydroxy-2-methylene-19-nor-homopregnacalciferol. The method includes the steps of condensing a bicyclic ketone with an allylic phosphine oxide to produce a protected 19-nor-pregnacalciferol analog, thereafter cleaving the protecting group to form 22-alcohol, converting the alcohol to an ester, reducing the ester to 17&bgr;-isopropyl-19-nor-vitamin D analog, and finally deprotecting the 17&bgr;-isopropyl derivative to form the desired compound.Type: ApplicationFiled: May 17, 2004Publication date: November 4, 2004Applicant: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Sumithra Gowlugari, Rafal R. Sicinski
-
Patent number: 6806262Abstract: Biologically active 19-nor vitamin D analogs substituted at C-2 in the A-ring with an ethylidene or an ethyl group. These compounds have preferential activity on mobilizing calcium from bone and either high or normal intestinal calcium transport activity which allows their in vivo administration for the treatment of metabolic bone diseases where bone loss is a major concern. These compounds are also characterized by high cell differentiation activity.Type: GrantFiled: May 31, 2001Date of Patent: October 19, 2004Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Rafal R. Sicinski
-
Patent number: 6787660Abstract: Vitamin D compounds of formula (I) with a label attached to a spacer group in the 3 position are disclosed. In the above formula (I), X is an optionally substituted hydrocarbon group with a length of 0.8-4.2 nm, optionally containing the heteroatoms S, O, N or P; Y is H or OH; A is a label capable of binding with high affinity to a protein; R is an optionally substituted hydrocarbon side chain of a D vitamin or a D vitamin metabolite. Also disclosed is the preparation of formula (I).Type: GrantFiled: February 20, 2001Date of Patent: September 7, 2004Assignees: Immundiagnostik AG, Biomedica GmbHInventors: Franz Paul Armbruster, Wolfgang Voelter, Jens Tampe, Christian Birkmayer
-
Publication number: 20040167105Abstract: This invention relates to 1,3-dihydroxy-20,20-dialkyl-vitamin D3 analogs of Formula (I): 1Type: ApplicationFiled: February 18, 2004Publication date: August 26, 2004Inventors: Percy Sarwood Manchand, Milan Radoje Uskokovic
-
Patent number: 6774251Abstract: A method of making 1&agr;-hydroxy-2-methylene-19-nor-homopregnacalciferol. The method includes the steps of condensing a bicyclic ketone with an allylic phosphine oxide to produce a protected 19-nor-pregnacalciferol analog, thereafter cleaving the protecting group to form 22-alcohol, converting the alcohol to an ester, reducing the ester to 17&bgr;-isopropyl-19-nor-vitamin D analog, and finally deprotecting the 17&bgr;-isopropyl derivative to form the desired compound.Type: GrantFiled: March 26, 2003Date of Patent: August 10, 2004Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Sumithra Gowlugari, Rafal R. Sicinski
-
Publication number: 20040152675Abstract: This invention discloses (20S)-1&agr;-hydroxy-2&agr;-methyl-19-nor-vitamin D3 and (20S)-1&agr;-hydroxy-2&bgr;-methyl-19-nor-vitamin D3 and pharmaceutical uses therefor. These compounds exhibit pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. These compounds also have very significant calcemic activity and therefore may be used to treat immune disorders in humans as well as metabolic bone diseases such as osteoporosis.Type: ApplicationFiled: January 22, 2004Publication date: August 5, 2004Applicant: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Rafal R. Sicinski, Pawel K. Grzywacz
-
Publication number: 20040138184Abstract: Provided is a crystallization method for reducing the level of impurities in calcipotriene in which a solution of a starting calcipotriene in a first process solvent, for example THF, is combined with second process solvent, for example methyl formate, and, after cooling, calcipotriene is isolated. The method can include a slurry step for reducing the level of residual first process solvent.Type: ApplicationFiled: November 18, 2003Publication date: July 15, 2004Inventors: Anchel Schwartz, Asher Maimon
-
Publication number: 20040132695Abstract: The present invention provides novel C24-sulfone analogs of 1&agr;,25-dihydroxy vitamin D3, compositions comprising these compounds and methods of using these compounds as selective inhibitors of CYP24. In particular, the compounds of the invention are useful for treating diseases which benefit from a modulation of the levels of 1&agr;,25-dihydroxy vitamin D3, for example, cell-proliferative disorders.Type: ApplicationFiled: July 3, 2003Publication date: July 8, 2004Inventors: Gary H. Posner, Kenneth Crawford, Hong Woon Yang, HeungBae Jeon, Mark Hatcher, Byung-Chul Suh, Jay White, Glenville Jones
-
Patent number: 6753435Abstract: An object of the present invention is to provide intermediates for the synthesis of 1&agr;-hydroxyvitamin D derivatives useful as drugs and processes for the preparation thereof.Type: GrantFiled: September 25, 2002Date of Patent: June 22, 2004Assignee: Teijin LimitedInventors: Masahiro Koga, Toru Minoshima
-
Patent number: RE39706Abstract: The present invention relates to calcipotriol hydrate—a new crystalline form of calcipotriol—with superior technical properties and with superior stability.Type: GrantFiled: January 15, 1993Date of Patent: June 26, 2007Assignee: Leo Pharma A/SInventors: Erik Torngaard Hansen, Niels Smidt Rastrup Andersen, Lene Hoffmeyer Ringborg